Immunotherapy shows promise against Hard-to-Treat colorectal cancer

NCT ID NCT06428487

Completed Disease control Sponsor: Blokhin's Russian Cancer Research Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tested the immunotherapy drug prolgolimab in 30 people with a specific type of colorectal cancer (MSI/dMMR) that had not spread. Participants received the drug for 6 months before planned surgery. The main goal was to see if the cancer completely disappeared in the removed tissue. The study is now complete, and results will show how well this approach works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Prolgolimab (an immunotherapy drug given as an infusion)
What this could lead to: If successful, this could point toward a way to shrink or eliminate colorectal tumors before surgery, potentially reducing the need for more aggressive treatments.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply to everyone. Immunotherapy can cause side effects like inflammation in healthy organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal neoplasm Microsatellite Instability

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Locations

N.N. Blokhin NMRCO

Moscow, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.